Inozyme Director Cashes Out as BioMarin Merger Closes at $4
Rhea-AI Filing Summary
Form 4 Overview: The filing details the final disposition of Inozyme Pharma, Inc. (INZY) equity held by director Axel Bolte in connection with the closing of BioMarin Pharmaceutical’s all-cash acquisition of the company on 1 July 2025.
- Common stock: 423,926 shares tendered and converted into cash at $4.00 per share, the agreed Merger Consideration.
- Stock options: • 234,176 options (exercise $2.02, exp. 6/19/2029) and • 159,187 options (exercise $2.77, exp. 4/22/2030) were automatically accelerated, cancelled and cashed out for the intrinsic value (Merger Consideration minus exercise price) per option share.
- After the transactions, the reporting person holds zero INZY securities; Inozyme is now a wholly-owned subsidiary of BioMarin and will cease public trading.
Investor takeaway: The Form 4 confirms that the merger has reached the final settlement stage, signalling the end of INZY as a standalone public equity and locking in the previously announced $4.00 cash payment for all former shareholders.
Positive
- Merger completion confirmed: Filing provides definitive evidence that BioMarin’s acquisition closed and cash consideration was delivered.
Negative
- Public float eliminated: INZY shareholders no longer participate in future upside; trading in the security will cease.
Insights
TL;DR Definitive insider Form 4 confirms BioMarin’s cash acquisition of INZY closed; all shares/options converted to cash, no equity remains outstanding.
The filing is largely administrative but materially confirms consummation of the May 16 2025 merger agreement. All public float is extinguished at $4.00 per share, a price that represented a premium when announced. Option acceleration and cash-out remove any overhang from outstanding awards. For arbitrageurs, the event date (7/1/25) marks final settlement, eliminating deal-closure risk. Post-close, INZY will be delisted and integrated into BioMarin. Rating reflects the information’s confirmatory value rather than incremental news.
TL;DR Director Bolte exits entire position; no governance impact as INZY dissolves into BioMarin.
The Form 4 shows complete divestiture of equity holdings by a board member through mandatory tender and option cash-out. Because INZY no longer exists as an independent entity, ongoing Section 16 reporting obligations terminate. Investors in BioMarin may focus on integration execution; INZY-specific governance risks are now irrelevant. The disclosure is routine yet final in nature.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 234,176 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 159,187 | $0.00 | -- |
| U | Common Stock | 423,926 | $4.00 | $1.70M |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger") Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
